Last reviewed · How we verify
biphasic human insulin 30
Biphasic human insulin 30 is a premixed insulin formulation that provides both rapid-acting and long-acting insulin coverage to regulate blood glucose levels in diabetes.
Biphasic human insulin 30 is a premixed insulin formulation that provides both rapid-acting and long-acting insulin coverage to regulate blood glucose levels in diabetes. Used for Type 1 diabetes mellitus, Type 2 diabetes mellitus.
At a glance
| Generic name | biphasic human insulin 30 |
|---|---|
| Sponsor | Novo Nordisk A/S |
| Drug class | Insulin (premixed biphasic formulation) |
| Target | Insulin receptor |
| Modality | Small molecule |
| Therapeutic area | Diabetes |
| Phase | FDA-approved |
Mechanism of action
This formulation contains 30% soluble (rapid-acting) human insulin and 70% isophane (intermediate-acting) human insulin, allowing for a single injection that provides both immediate postprandial glucose control and basal insulin coverage. The rapid-acting component addresses mealtime glucose spikes, while the intermediate-acting component provides sustained glucose control between meals and overnight.
Approved indications
- Type 1 diabetes mellitus
- Type 2 diabetes mellitus
Common side effects
- Hypoglycemia
- Weight gain
- Injection site reactions
- Lipodystrophy
Key clinical trials
- Use of a Novel SUBCUTaneous Preparation of Furosemide to Facilitate Early Supported Discharge of Patients With Heart Failure (PHASE2)
- Comparison of Thrice-Daily Premixed Human Insulin with Basal-Bolus Therapy Among Patients with Poorly Controlled Type 2 Diabetes Mellitus (PHASE4)
- Embryo Developmental Potential in a Novel 2-step IVM System (NA)
- Observational Study of Patients Using NovoMix® 30 or Levemir® for Treatment of Type 1 or Type 2 Diabetes
- INITIATE Plus (INITiation of Insulin to Reach A1c TargEt) Study (PHASE4)
- Efficacy of Biphasic Insulin Aspart 30 in Subjects With Type 2 Diabetes Failing on OADs (PHASE4)
- Safety and Effect of Biphasic Insulin Aspart 50 in Patients With Type 2 Diabetes Mellitus. (PHASE3)
- Comparison of Two Treatment Regimens in Patients With Type 2 Diabetes After Short-term Intensive Insulin Therapy (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- biphasic human insulin 30 CI brief — competitive landscape report
- biphasic human insulin 30 updates RSS · CI watch RSS
- Novo Nordisk A/S portfolio CI